Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officer.

Appointment:

On March 23, 2021 David R. Koos was appointed Chairman and Sole Director of Regen Biopharma, Inc. On March 23, 2021 David R. Koos was appointed Chief Executive Officer, President, Secretary and Treasurer of Regen Biopharma, Inc.

On March 23, 2021 David R. Koos was appointed Chairman and Sole Director of KCL Therapeutics, Inc. On March 23, 2021 David R. Koos was appointed Chief Executive Officer, President, Secretary and Treasurer of KCL Therapeutics, Inc.

KCL Therapeutics, Inc. is a wholly owned subsidiary of Regen Biopharma, Inc.



Education:



DBA - Finance (December 2003)

Atlantic International University

Ph.D. - Sociology (September 2003)

Atlantic International University

MA - Sociology (June 1983)

University of California - Riverside, California





Five Year Employment History:

David R. Koos, 62 has served as Chairman of the Board of Directors, Chief Executive Officer, President, Secretary and Treasurer of SYBLEU INC., a biotechnology company, from June 12, 2020 to the present. David R. Koos served as Chief Financial Officer of SYBLEU INC. from June 12, 2020 to July 21, 2020. On March 23, 2021 David R. Koos assumed the position of sole officer and director of Zander Therapeutics, Inc., a biotechnology company.





Position:                        Company Name:              Employment Dates:
Chairman, President, Chief       Entest Group, Inc.         June 19, 2009 to
Executive Officer,                                          November 28, 2018
Secretary, Acting Chief
Financial Officer,
Principal Accounting
Officer
Chairman, President, Chief       Entest BioMedical,         August 22,2008 to the
Executive Officer,               Inc.( a California         Present
Secretary, Chief Financial       corporation)
Officer, Principal
Accounting Officer
Chairman and CEO                 Regen BioPharma, Inc.      April 24, 2012 to
                                                            January 22,2020
Acting CFO                       Regen BioPharma, Inc.      April 24, 2012 to
                                                            February 11, 2015
President                        Regen BioPharma, Inc.      May 29, 2013 to
                                                            October 9, 2013
Chairman, CEO                    Zander Therapeutics,       February 2017 to
                                 Inc.                       January 22,2020
Sole Officer and Director        Cell Source Research,      March 24, 2003 to the
                                 Inc.                       Present
Chairman, President, CEO         Bio-Matrix Scientific      June 14, 2006
and Acting CFO                   Group, Inc.                (Chairman) to July
                                                            31;2019 June 19, 2006
                                                            (President, CEO and
                                                            Acting CFO); June 19,
                                                            2006 (Secretary) to
                                                            July 31, 2019
Chairman & CEO                   BST Partners Inc.          November 30, 2018 to
                                                            the Present
                                 (A California
                                 Corporation)
Chairman & CEO                   BST Partners Inc.          March 17, to 2017 to
                                                            the Present
                                 (A Wyoming
                                 Corporation)




Related Party Transactions:

As of June 20, 2019 the registrant was indebted to David R. Koos in the amount of $5,840

As of June 30, 2020 the registrant was indebted to Zander Therapeutics, Inc. in the amount of $56,900.

As of June 30, 2019 Zander Therapeutics, Inc. was party to an agreement with KCL Therapeutics, Inc. whereby Zander was granted an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by KCL (" License IP") for non-human veterinary therapeutic use.

Consideration.

It was resolved by the Board of Directors of the registrant that as consideration for agreeing to serve as an officer and director of Regen Biopharma, Inc. David R. Koos shall be awarded 10,000 shares of a newly designated series of nonconvertible supervoting Preferred Stock ("Supervoting Stock"). With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Supervoting Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Supervoting Stock owned by such holder times five hundred thousand.

Departure of Officer and Director:

On March 23, 2021 Todd S. Caven resigned from his position as Chairman of the Board of Directors, Chief Executive Officer and any and all other offices he may hold of Regen BioPharma ,Inc. and KCL Therapeutics Inc. As of March 23, 2021 David R. Koos became the sole officer and director of both the registrant and KCL Therapeutics, Inc.

Item 1.01 Entry into a Material Definitive Agreement.

On March 23,2021 Todd S. Caven ( "Caven") entered into an agreement with Regen BioPharma, Inc. ( "Company") whereby Caven would assist the Company in obtaining the agreement of the creditors of the Company ("Creditors" or singularly "Creditor") to settle any and all claims against the Company upon terms acceptable to the Company ("Agreement").

The term of the Agreement shall be from March 24,2021 to March 24,2022.

In the event that due to the efforts of Caven with regard to any Creditor the Company agrees to enters into a Settlement and Release Agreement with such Creditor acceptable to the Company for an amount which is less that the original debt owed ("Settlement") Caven shall receive an amount to be negotiated by and between the Parties on a case by case basis as to each applicable Creditor.

The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.

Item 9.01 Exhibits



Exhibit 99.1 Letter of resignation
Exhibit 10.1 Agreement




  2

© Edgar Online, source Glimpses